Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treatment-resistant schizophrenic patients

J M Kane1

  • 1Department of Psychiatry, Hillside Hospital, Glen Oaks, NY 11004, USA.

The Journal of Clinical Psychiatry
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Canadian Surgery Forum: Abstracts of presentations to the Annual Meetings of the Canadian Association of Bariatric Physicians and Surgeons, Canadian Association of General Surgeons, Canadian Association of Thoracic Surgeons, Canadian Hepato-Pancreato-Biliary Society, Canadian Society of Surgical Oncology, Canadian Society of Colon and Rectal Surgeons, London, Ont. Sept. 15-18, 2011.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

How and when to use clozapine.

Acta psychiatrica Scandinavica·2019
Same author

Detecting relapse in youth with psychotic disorders utilizing patient-generated and patient-contributed digital data from Facebook.

NPJ schizophrenia·2019
Same author

Clozapine as an early-stage treatment.

Acta psychiatrica Scandinavica·2018
Same author

Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia.

Acta psychiatrica Scandinavica·2018
Same author

Abnormalities of gait caused by ankle arthritis are improved by ankle arthrodesis.

The bone & joint journal·2016
Same journal

Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

The Journal of clinical psychiatry·2026
Same journal

Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

The Journal of clinical psychiatry·2026
Same journal

Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

The Journal of clinical psychiatry·2026
Same journal

Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

The Journal of clinical psychiatry·2026
Same journal

Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

The Journal of clinical psychiatry·2026
Same journal

The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

The Journal of clinical psychiatry·2026
See all related articles

For schizophrenia patients unresponsive to standard antipsychotics, clozapine demonstrates effectiveness in trials. Risperidone may also offer benefits for treatment-resistant schizophrenia, though further study is needed.

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Medicine

Background:

  • Schizophrenia treatment often involves antipsychotic medications.
  • A significant portion of patients exhibit resistance or poor response to standard antipsychotics.
  • Alternative strategies like dose adjustment or medication changes yield limited success.

Purpose of the Study:

  • To evaluate the efficacy of clozapine in patients with treatment-resistant schizophrenia.
  • To explore the potential of risperidone as an alternative for patients with poor or partial response to antipsychotics.

Main Methods:

  • Three prospective, randomized, double-blind trials assessed clozapine's effectiveness.
  • Limited data exists on risperidone's use in treatment-resistant schizophrenia patients.

Related Experiment Videos

Main Results:

  • Clozapine proved effective in a subset of patients with poor or partial response to prior antipsychotic treatments.
  • Risperidone's efficacy in this specific patient group requires more extensive investigation.

Conclusions:

  • Clozapine is a viable option for managing treatment-resistant schizophrenia.
  • Further research is warranted to establish risperidone's role in managing antipsychotic-resistant schizophrenia.